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In the search for biomarkers of
synapse loss associated with Alz-
heimer’s disease (AD), we used
shotgun proteomics to identify a
panel of 9 synaptic proteins de-
tectable in human cerebrospinal
fluid (CSF). Expression at the hu-
man synapse was verified using
super resolution microscopy. Using
SRM, we monitored the panel in
CSF from 3 independent clinical
cohorts. We report 6 synaptic bio-
markers that demonstrate changes
in preclinical AD prior to markers of
neurodegeneration, which could




• Proteomic analysis of cerebrospinal fluid and identification of synaptic component.
• Use of super resolution microscopy to verify synapse-specificity in human tissue.
• Selective reaction monitoring MS (SRM) of synaptic panel in 3 cohorts of Alzheimer’s disease cerebro-
spinal fluid.
• Synaptic protein changes precede tau in preclinical Alzheimer’s disease.
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Changes in Synaptic Proteins Precede
Neurodegeneration Markers in Preclinical
Alzheimer’s Disease Cerebrospinal Fluid*
Alberto Lleó‡§ §§§¶¶¶, Raúl Núñez-Llaves§¶ ¶¶¶, Daniel Alcolea‡§, Cristina Chiva**,
Daniel Balateu-Paños¶, Martí Colom-Cadena§¶, Gemma Gomez-Giro¶,
Laia Muñoz§¶, Marta Querol-Vilaseca§¶, Jordi Pegueroles§¶, Lorena Rami‡‡,
Albert Lladó‡‡, José L. Molinuevo‡‡, Mikel Tainta§§¶¶, Jordi Clarimón§¶,
Tara Spires-Jones, Rafael Blesa‡§, Juan Fortea‡§, Pablo Martínez-Lage§§,
Raquel Sánchez-Valle‡‡, Eduard Sabidó**, Àlex Bayés***‡‡‡, and Olivia Belbin§¶
A biomarker of synapse loss, an early event in Alzheimer’s
disease (AD) pathophysiology that precedes neuronal
death and symptom onset, would be a much-needed
prognostic biomarker. With direct access to the brain
interstitial fluid, the cerebrospinal fluid (CSF) is a potential
source of synapse-derived proteins. In this study, we
aimed to identify and validate novel CSF biomarkers of
synapse loss in AD. Discovery: Combining shotgun pro-
teomics of the CSF with an exhaustive search of the
literature and public databases, we identified 251 synaptic
proteins, from which we selected 22 for further study.
Verification: Twelve proteins were discarded because of
poor detection by Selected Reaction Monitoring (SRM).
We confirmed the specific expression of 9 of the remain-
ing proteins (Calsyntenin-1, GluR2, GluR4, Neurexin-2A,
Neurexin-3A, Neuroligin-2, Syntaxin-1B, Thy-1, Vamp-2) at
the human synapse using Array Tomography microscopy
and biochemical fractionation methods. Exploration: Us-
ing SRM, we monitored these 9 synaptic proteins (20
peptides) in a cohort of CSF from cognitively normal con-
trols and subjects in the pre-clinical and clinical AD
stages (n  80). Compared with controls, peptides from 8
proteins were elevated 1.3 to 1.6-fold (p < 0.04) in prodro-
mal AD patients. Validation: Elevated levels of a GluR4
peptide at the prodromal stage were replicated (1.3-fold,
p  0.04) in an independent cohort (n  60). Moreover, 7
proteins were reduced at preclinical stage 1 (0.6 to 0.8-
fold, p < 0.04), a finding that was replicated (0.7 to 0.8-
fold, p < 0.05) for 6 proteins in a third cohort (n  38). In a
cross-cohort meta-analysis, 6 synaptic proteins (Calsyn-
tenin-1, GluR4, Neurexin-2A, Neurexin-3A, Syntaxin-1B
and Thy-1) were reduced 0.8-fold (p < 0.05) in preclinical
AD, changes that precede clinical symptoms and CSF
markers of neurodegeneration. Therefore, these proteins
could have clinical value for assessing disease progres-
sion, especially in preclinical stages of AD. Molecular &
Cellular Proteomics 18: 546–560, 2019. DOI: 10.1074/mcp.
RA118.001290.
Synapse loss is a fundamental process underlying many
neurological and psychiatric diseases including, but not lim-
ited to Alzheimers Disease (AD)1, Parkinson’s disease, Lewy
body diseases, schizophrenia and depression (1–3). There-
fore, a biomarker capable of detecting synapse loss in living
individuals has the potential to be a surrogate marker for
disease severity, which would make an excellent addition to
the biomarker arsenal for a wide range of neurological dis-
eases. To search for novel synaptic biomarkers, we have
selected AD as a disease model for synaptopathy. Synapse
loss is an early event in AD, which precedes neuronal death (1)
and evidence from animal models indicates that the synapse
is the target of both AD pathological proteins, A and tau (4).
AD can be conceptualized as a continuum of preclinical and
clinical phases, based on the clinical syndrome and biomark-
ers of brain amyloidosis and tau-mediated neurodegenera-
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tion. In this conceptualization, patients with mild cognitive
impairment (5) or dementia (6) who are positive for AD bio-
markers are labeled as patients with MCI because of AD
(prodromal AD) or dementia because of AD (6). Likewise, the
current guidelines from the National Institute on Aging-Al-
zheimer Association (NIA-AA) conceptualize three preclinical
stages of AD (7) whereby cognitively normal subjects with
signs of brain amyloidosis (preclinical Stage 1), amyloidosis
and neurodegeneration (preclinical Stage 2) or both markers
as well as subtle cognitive decline (preclinical Stage 3). Al-
though markers of A and tau pathology are excellent diag-
nostic biomarkers for AD, a marker of synapse degeneration
would be invaluable for assessing disease progression in
at-risk subjects. In this regard, many researchers have turned
to biochemical markers in CSF, a biofluid with direct access to
the central nervous system that can be extracted from living
individuals by lumbar puncture.
Previous studies have reported elevated CSF levels of in-
dividual synaptic proteins such as neurogranin (8), SNAP-25
(9), synaptotagmin-1 (10) in AD dementia patients and neur-
exins 1, 2 and 3, and neurofascin (11) in prodromal AD pa-
tients. Although these findings support the idea that synaptic
proteins in CSF may be informative in AD, the previously
reported correlation between CSF levels of synaptic proteins
with CSF levels of tau suggest that widespread neuronal loss
could be a confounding factor when studying synaptic pro-
teins in the CSF, particularly at clinical disease stages. The
CSF profile of synaptic proteins in preclinical stages of AD,
before widespread neurodegeneration has taken hold has not
been explored in detail. This is an important aspect because
a good CSF marker of underlying synaptic degeneration
should demonstrate changes that precede those of neurode-
generation markers. The progressive staging of neurodegen-
eration markers in AD, make this disease an excellent model
system to evaluate the potential relationship between CSF
levels of proposed synaptic biomarkers and existing markers
of neurodegeneration.
Here we report (1) a systematic proteomic study of the CSF
with a thorough characterization of the synaptic composition
(discovery), (2) development of Tier 2 SRM assays for a set of
CSF proteins whose expression was confirmed at the human
cortical synapse or in synapse-associated structures (verifi-
cation), (3) assessment of the CSF profile of the synaptic
panel in a clinical cohort that includes cognitively normal
subjects and AD preclinical and clinical stages (exploration),
and (4) confirmation in independent clinical AD cohorts (clin-
ical validation).
EXPERIMENTAL PROCEDURES
Experimental Design and Statistical Rationale—This study is di-
vided into the following stages: Discovery stage; peptide and protein
identification in 7 pools of 60 CSF samples. Verification stage; Tier 2
SRM assay development for selected peptides in CSF and patholog-
ical study of selected proteins in human post-mortem tissue from 6
donors. Exploration stage; SRM of selected peptides in CSF from
cognitively normal controls and pre-clinical and clinical stages of the
AD continuum (n  80) prospectively recruited from the Sant Pau
Initiative in Neurodegeneration (SPIN) cohort at Hospital Sant Pau,
Barcelona and by the CITA Foundation, Donostia (exploratory cohort).
Validation stage; SRM of selected peptides in an independent collec-
tion of CSF (n  60) prospectively recruited from the collection at
Hospital Clinic, Barcelona (validation cohort-1) and an independent
selection (validation cohort-2) of cognitively normal controls and pre-
clinical stage 1 subjects (n  38) from the SPIN cohort. Where possible,
subjects included in each group were age and sex-matched. CSF
samples were run on the mass spectrometer in a randomized order with
respect to diagnostic group. No technical replicates were included in
the SRM study. Biological controls for SRM included cognitively normal
individuals (exploratory Cohort, n  20, validation cohort-1, n  18,
validation cohort-2, n  20). Biological replicates for SRM included
patients and volunteers grouped according to established diagnostic
criteria. As technical controls for SRM, BSA controls were run between
each sample (shotgun and targeted LC-MS/MS).
Clinical CSF Cohorts—All participants gave their written consent.
The study (IIBSP-BIO-2015–76) was approved by the local ethics
committee following the ethical standards recommended by the Hel-
sinki Declaration. All subjects were evaluated by neurologists with
expertise in neurodegenerative diseases, by neuropsychologists us-
ing a previously published neuropsychological battery (12) and as-
sessed for established AD biomarkers, namely brain amyloidosis (low
CSF levels of A1–42 or positive amyloid PET imaging) and neuro-
degeneration (high CSF levels of total tau or phosphorylated tau)
based on local cut-offs. These cut-offs have high specificity and
sensitivity to distinguish AD dementia patients from controls (13).
Diagnoses of prodromal AD and AD dementia were made according
to NIA-AA guidelines (5, 6). Subjects within the normal range following
formal neuropsychological evaluation, when accounting for age and
education (mostly recruited among patients’ caregivers), were classi-
fied into preclinical AD stages in accordance with NIA-AA guidelines
(7).
CSF Collection, Biomarker Assessment, and APOE Genotyping—
CSF samples were collected following international consensus rec-
ommendations (14) as previously described (13). Samples had been
previously stored at 80 °C and had not been thawed prior to anal-
ysis. Commercially available ELISA kits were used to determine levels
of CSF A1–42 (Innotest
TM A1–42, Fujirebio-Europe, Belgium), total
Tau (InnotestTM hTAU Ag), Tau phosphorylated at threonine residue
181 (InnotestTM Phospho-Tau 181P). Our laboratory has extensive
experience in CSF biomarker determination and participates in the
Alzheimer’s Association external quality control program for CSF
biomarkers (15).
Post-mortem Human Brain Samples—All post-mortem brain tissue
used in this study was collected by the Neurological Tissue Bank at
Hospital Clínic (IDIBAPS, Barcelona). The study (IIBSP-ATM-2012–
46) was approved by the local Ethics Committee of both the Tissue
Bank and Sant Pau Research Institute. Fresh brain tissue used for
array tomography was collected from the superior frontal cortex of a
female donor who died at the age of 83 and showed low AD pathology
(Braak stage II). Pre-collected frozen tissue blocks from 6 donors (4
male, 2 female, mean age-at-death 66 years) without AD pathology
were used for synaptosome and PSD enrichment.
1 The abbreviations used are: AD, Alzheimer’s disease; AT, array
tomography; CSF, cerebrospinal fluid; FDR, false discovery rate; GO,
gene ontology; LC, liquid chromatography; MS/MS, mass spectrom-
etry; NIH-AA, National Institute of Health-Institute of Aging; PSD-95,
post-synaptic density; SCX, strong cation exchange; SRM, selected
reaction monitoring.
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Shotgun Liquid Chromatography Mass Spectrometry (LC-MS/
MS)—Where indicated, immunodepletion was performed using the
ProteoPrep® Immunoaffinity Albumin & IgG Depletion Kit (Sigma-
Aldrich, Missouri). Six pools each containing CSF from 10 individuals
were precipitated with acetone and protein content was quantified by
Bradford assay. Samples (50 ug) were reduced in 10 mM DTT, alky-
lated with 55 mM IAA, and, digested in-solution with trypsin and LysC
overnight and desalted using a Desalted MicroSpin Column (GE
healthcare, UK). Where indicated, samples were fractionated by
strong cation exchange (SCX; Empore Disks Anion Exchange-SR,
Sigma-Aldrich). An equivalent of 5 l of each CSF Sample was
analyzed using a LTQ-Orbitrap Velos Pro mass spectrometer (Thermo
Fisher Scientific, San Jose, CA) coupled to a nano-LC (Proxeon,
Odense, Denmark) equipped with a reversed-phase chromatography
2-cm C18 pre-column (Acclaim PepMap-100, Thermo; 100 m i.d., 5
m), and a reversed-phase chromatography 25 cm C18 column
(Nikkyo Technos, Japan; m i.d., 1.9 m) using a data-dependent
acquisition mode. Acquired data were analyzed using the Proteome
Discoverer software suite (v1.4.1.14, Thermo Fisher Scientific), and
the Mascot search engine (v2.5.1, Matrix Science) was used for
peptide identification. Data were searched against the Swiss Prot
Human Protein database plus the most common contaminants (ver-
sion 2014, 20884 entries). A precursor ion mass tolerance of 7 ppm at
the MS1 level was used, and up to three missed cleavages for trypsin
were allowed. The fragment ion mass tolerance was set to 0.5 Da.
Oxidation of Methionine and N-terminal protein acetylation was de-
fined as variable modification and carbamidomethylation of Cysteines
was set as fixed modification. The identified peptides were filtered at
5% FDR calculated using a target-decoy database strategy. For each
identified peptide, peptide peak areas were obtained as extracted ion
chromatograms and protein abundances were estimated with the
average peak area of the three most intense peptides per protein. For
characterization of the CSF proteome, proteins without a reviewed
Uniprot identifier were excluded. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium via
the PRIDE (16) partner repository (https://www.ebi.ac.uk/pride/
archive) with the data set identifier PXD010356.
Database and Literature Curation—A systematic search of PubMed
(www.pubmed.com) for proteomic studies was performed using the
search terms “Cerebrospinal fluid”/“CSF,” & “proteome”/“proteom-
ics” & “human,” for the CSF proteome (April 2013) and “synapto-
some”/”synapse”/“post-synaptic density” & “proteome”/“proteom-
ics” & and “human”/”mouse”/”rat,” for the synapse proteome (April
2014). Only publications in English were reviewed. All identified pro-
teins were extracted either directly from the published material or
where available, from the PRIDE repository. All proteins with a known
function related to the synapse were retrieved from 4 publicly avail-
able databases. Specifically, all proteins annotated with a GO related
to the synapse were retrieved from AmiGO2 version 2.3.2 (http://
amigo2.geneontology.org/amigo) using the search terms “dendritic
spine,” “synapse,” “synaptic,” transmission of nerve impulse” and
“neurotransmitter”. All proteins annotated to “Glutamatergic syn-
apse,” “Cholinergic Synapse,” “Serotonergic synapse,” “GABergic
synapse,” “Dopaminergic synapse,” “Synaptic vesicle cycle,” ”Long-
term potentiation,” ”Long-term depression,” “Retrograde endocan-
nabinoid signaling” according to the Kyoto Encyclopedia of Genes
and Genomes were retrieved from http://www.kegg.jp. All proteins
with “neurotransmitter release,” “synapse,” “synaptic,” or “synapto-
genesis” as an annotated function were retrieved from Uniprot
(www.uniprot.org). Because each data source used distinct protein
identifiers that, in some cases, had been retired or updated, a unique,
reviewed Uniprot identifier was assigned to each protein using the
bioinformatic gene identification conversion tools, PIR (http://pir.
georgetown.edu) and Bio-Mart (http://www.ensembl.org/biomart) to
avoid duplication across studies. Proteins without a reviewed Uniprot
identifier were removed from the study.
Synaptosome Enrichment—All steps were performed at 4 °C. 200
mg chunks were cut from frozen frontal cortex tissue blocks and
homogenized in cold Buffer A (0.32 M sucrose, 1 mM NaHCO3, 1 mM
MgCl2, 0.5 mM CaCl2, 1:2500 phenylmethylsulfonyl fluoride, 1 g/ml
aprotinin, 1 g/ml leupeptin). Homogenates were centrifuged (1400 
g, 10 min) and the supernatant transferred to a new tube. The pellet
was resuspended in cold Buffer A and the previous step repeated
with centrifugation at 710  g. The two supernatants were combined
and centrifuged (710  g). The supernatant was subjected to a final
centrifugation (30,000  g, 15 min). The pellet was resuspended in
Buffer B (0.32 M sucrose, 1 mM NaHCO3), layered over a sucrose
gradient (0.85 M, 1 M, 1.2 M) and centrifuged (82,500  g, 2 h). The
synaptosomal fraction (a thick white band at the 1–1.2 M interface)
was collected, diluted in 4x volume of Buffer B. An aliquot was
centrifuged (48,200  g, 20 min) and the pellet (synaptosome) resus-
pended in Buffer C (50 mM Tris pH 7.4, 1% SDS) and stored at
80 °C. The remaining aliquot was diluted in equal volume Buffer D
(50 mM Tris pH 7.4) and 1 volume of 2% Triton-X, incubated for 10
min and centrifuged (maximum velocity, 30 min). The pellet (post-
synaptic density; PSD) was re-suspended in Buffer C and stored at
80 °C.
Array Tomography—The array tomography protocol was applied
using previously described methods (17, 18). Briefly, a 1 cm3 section
was taken from the superior frontal cortex was fixed, dehydrated and
polymerized in 100% LR-white resin. The embedded samples were
sectioned using a diamond knife (Diatome, UK) creating 20 serial 70
nm thick sections, which were mounted onto coverslips. The ultrathin
ribbons were washed with Tris buffer and blocked for 5 min. Primary
antibodies used were as mentioned above with the following excep-
tions; anti-Tenascin-R (Abcam, UK; ab121916) anti-GluR2, anti-Neuroli-
gin-2, anti-Neurexin2 (Merck Millipore, Massachusetts; MAB397,
AB15510, ABN97), anti-synaptophysin (Osenses, Australia; oss00029w)
and anti-PSD95 (Synaptic Systems, Germany; 124014), alexa-tagged
secondary antibodies (Thermo Fisher Scientific). Coverslips were
mounted onto the slides using Slowfade Gold with DAPI (Thermo Fisher
Scientific). Images were captured using a fully automated epifluores-
cence upright microscope (custom adapted BX51, Olympus, Pennsyl-
vania) with a 64  1.2 NA Plan Apochromat objective. Image analysis
was performed using Matlab (Mathworks). The script has been depos-
ited at https://github.com/MemoryUnitSantPau with the name SynSeg.
Images from serial sections were stacked, aligned, thresholded and the
nonspecific staining (not present in at least 2 consecutive sections)
removed using a local threshold-based algorithm. 3-D reconstructions
of representative synapses were generated using the ImageJ Volume
Viewer plug-in with tricubic smooth interpolation.
SDS-Page and Western Blotting—The total protein content of ho-
mogenate, synaptosome and PSD enriched fractions was quantified
by bicinchoninic acid assay. Aliquots containing 20 g total protein
were boiled, diluted in loading buffer (100 mM Tris-HCL, 4% SDS,
20% glycerol, 200 mM DTT and 200 mM -mercaptoethanol) and
loaded onto a 12% Tris-Tricine gel and electrophoresed. Proteins
were transferred to a nitrocellulose membrane, which was immuno-
stained using the following antibodies; anti-CLSTN1, anti-Synapto-
physin, anti-Thy1, (Abcam; ab134130, ab8049, ab133350), anti-
GluR2, anti-GluR4, anti-Vamp2, anti-PSD95 (Cell Signaling; 13607,
8070, 13508, 3450), Anti-neuroligin-2, anti-Syntaxin-1B (Synaptic
Systems; 129203, 110403), anti-Neurexin3, anti-Tenascin R (Thermo
Fisher; PA5–47714, PA5–47546), fluorescent dye-conjugated sec-
ondary antibodies (Li-COR Biosciences, Nebraska).
Targeted Liquid Chromatography Mass Spectrometry (LC-SRM)—
Fifty-four proteotypic peptides (7 to 20 amino acids long) with tryptic
terminals corresponding to 22 proteins brought forward from the
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shotgun data were selected based on previous LC-MS/MS data and
database searches (Peptide Atlas). For each targeted peptide, corre-
sponding crude heavy peptides were synthesized with 13C6
15N4
(Arg), or 13C6
15N2 (Lys) isotopes (Peprotech SRM custom peptides,
grade 2, Thermo Fisher Scientific) for use as reference internal stand-
ards in the CSF samples (Thermo Fisher), and to generate a library of
MS/MS spectra for the selection of interference-free transitions for
the peptides or interest. Individual CSF samples were precipitated
with acetone and redissolved in 6 M urea before reduction (10 mM,
DTT), alkylation (55 mM, IAA) and in-solution digestion with LysC and
Trypsin (1:10, 37 °C, overnight). Isotopically-labeled peptides were
spiked in each sample, and an equivalent of 5 l of each sample was
analyzed in a 120-min gradient (0–35% ACN0.1%FA) in SRM mode
using a triple quadrupole-Qtrap mass spectrometer (5500 QTrap,
Sciex, Massachussetts) coupled to a nano-LC chromatography col-
umn (300 l/min, 25-cm C18 column, 75 m I.d., 2 m particle size).
BSA control samples were analyzed between runs for instrument
quality control. Transitions were visualized and analyzed using Sky-
line 3.5 and peak picking was manually reviewed based on the
co-elution of the reference and endogenous peptides, peak shape
and correlation of transition rank intensities between the reference
and endogenous transitions. Of the initial 54 targeted peptides, 32
were eliminated from the study because of poor detection in a pilot
detection experiment with 5 CSF samples. The remaining 22 peptides
were taken forward for further monitoring in the exploratory and
validation cohorts. Peptide stability was assessed by injecting a pool
of all the samples over the duration of the mass spectrometric meas-
urements and monitoring the peak area of the standard peptides.
SRM transitions were processed using the dataProcess function of
MSstats v3.5 package in R (19). Specifically, the EqualizeMedians
function was used to normalize the data using the transition intensi-
ties of the isotope-labeled standard peptides. This method was cho-
sen as it assumes that the samples of a data set are separated by a
constant and scales the samples so that they have the same median.
The results were not significantly altered when compared with normal-
ization using the alternative Quantile method in MSstats. The normal-
ized data were summarized (TMP: Tukey’s Median Polish) according to
either peptide or protein. Transitions with between run interference were
identified using the “betweenRunInterferenceScore” (cut-off  0.8).
Samples with log base-2 endogenous intensities under the cut-off des-
ignated by the MSstats package for each cohort (9.5211, 8.4337, and
8.5219, respectively) were considered as censored missing values. The
mass spectrometry-based targeted proteomics data have been depos-
ited to the Panorama repository (https://panoramaweb.org/5Jugvs.url)
and the PRIDE repository with the identifier PXD012138.
Statistical Analysis—To determine enrichment of synaptic prteins in
synaptosome and PSD-enriched fractions isolated from post-mortem
brain tissue, the intensity of bands corresponding to the synaptic
proteins on SDS-PAGE membranes were quantified using Odyssey
software (Li-COR Biosciences). The ratio of each fraction relative to
that of the homogenate (enrichment) was calculated. Because enrich-
ment ratios for the 10 synaptic proteins did not clearly deviate from a
Gaussian distribution (Kolmogorov-Smirnov p  0.1), mean enrich-
ment ratios were compared in synaptosome and PSD fractions versus
homogenates by One-Way Analysis of Variance (with Dunnett’s post-
hoc test). For SRM data, log2 fold-changes for each preclinical and
clinical AD stage relative to controls were calculated using a mixed
effect linear regression model (GroupComparison function in
MSstats). For meta-analyses of the SRM data from the three cohorts,
p values were calculated according to Fisher’s method using the
“metap” package in R. Where stated, adj.p values refers to p values
adjusted using the Benjamini-Hochberg method to account for mul-
tiple testing.
RESULTS
Discovery Stage - Characterizing the Synaptic Component
of the CSF—To characterize the CSF proteome, we per-
formed a discovery proteomics screen of 7 CSF pools each
containing samples from 10 individuals extracted from either
cognitively normal controls (5 pools), AD patients (1 pool) or a
mixture of both (1 pool), varying the LC-MS/MS conditions to
optimize protein yield. Further details of the sample pools,
LC-MS/MS conditions and identified contaminants can be
found in supplemental Table S1. We found that depletion of
abundant IgGs and albumins increased the protein yield by
115% and that SCX fractionation had a greater effect on
protein yield (186% increase compared with runs without
SCX, 6 h LC) than extended LC times (141% increase follow-
ing SCX  6 h LC compared with SCX  2 h LC). Overall, IgG
and albumin depletion, SCX fractionation with 6 h LC resulted
in the greatest protein yield (mean yield  1,259 proteins,
range  702–1,615). Across all LC-MS/MS runs, we identified
18,785 peptides (supplemental Table S2) corresponding to
2742 unique proteins (supplemental Table S3).
To gain a more complete picture of the CSF proteome, we
performed a complementary search of published proteomic
studies of CSF extracted from cognitively or neurologically nor-
mal individuals. The search identified 10 independent studies
(20–29) listed in Table IA. We extracted 3662 unique proteins
supplemental Table S3) from the 9 studies for which data were
publicly available. By combining our dataset with the datasets
from the literature, we report 4315 proteins that have been
identified in cognitively/neurologically normal CSF and a further
296 proteins that we detected only in pools from AD patients
and/or mixed pools.
To identify the synaptic component of the CSF, we next
sought to characterize the human synaptic proteome also
using publicly available data, but in this case related to the
characterization of the synapse. Here we have defined the
synaptic proteome as proteins that (1) have an annotated
synaptic function according to 4 selected public databases
(see Experimental Procedures), and (2) have been detected in
at least 1 of 23 published proteomic studies (30–50) of syn-
apse-enriched fractions from rodent or human brain tissue
(Table IB–ID). supplemental Table S4 shows the 537 proteins
that satisfy these criteria. Cross-referencing the CSF with this
shortlist, we identified 251 synaptic proteins that are detect-
able in the CSF by shotgun mass spectrometry (supplemental
Table S5). Using these criteria, we report that 6% of CSF
proteins are of synaptic origin.
Verification Stage - Selecting a Panel of Synapse-specific
Proteins Suitable for SRM—The 251 synaptic proteins that
were detectable in the CSF were manually curated and an
initial list of 22 proteins that participate in one or more core
synaptic process (Calsyntenin-1 (51), GABAB receptor 1 (52),
GABAA receptor A2 (53), GABAA receptor A3, GluR2 (54),
GluR4 (55), mGluR1 (56), Munc18 (57), Neurexin-2A (58) Neur-
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exin-3A (59), Neuroligin-1 (60), Neuroligin-2 (61), Neuroplastin
(62), Synapsin-1 (63), Synaptic Ras-GAP 1 (64), Synaptic ves-
icle glycoprotein 2B (65), Synaptotagmin-1 (66), Syntaxin-1A
(67), Syntaxin-1B, Tenascin-R (68), Thy-1 and Vamp-2 (69))
were selected with the goal of defining a subset of proteins
that is amenable for multiplex quantification. To confirm de-
tection of the 22 proteins in CSF by targeted mass spectrom-
etry, we developed SRM assays using 54 isotopically-labeled
peptides corresponding to the 22 selected proteins to be
used as internal references. We monitored the peptides in a
preliminary set of 5 CSF samples and eliminated 32 peptides
from the study because of poor detection (supplemental Ta-
ble S6).
To investigate the specificity of the expression of the re-
maining 10 proteins in human synapses, we applied array
tomography (AT) microscopy to our panel of proteins in hu-
man cortical tissue. AT is particularly suited to the study of
synapses as it provides improved spatial resolution in the
axial plane compared with other light microscopy techniques
(i.e. confocal microscopy). By obtaining ultrathin (70 nm) tis-
sue sections, single synapse terminals may be identified.
Representative 3D reconstructions of single synapse termi-
nals clearly show the expression of 9 of the panel proteins
directly at the synapse, marked by pre (synaptophysin) and
post (PSD-95) synaptic markers (Fig 1A). In contrast, Tenas-
cin-R was found surrounding the synapse without making
TABLE I
Details of published proteomic studies of the CSF and synapse. The number of proteins identified by at least 1 proteotypic peptide in each study
of (A) the CSF, (B) whole synapse, (C) active zone and synaptic vesicles and (D) PSD/MAGUK-associated signalling complexes (MASC) is
shown. *Data were not publicly available for retrieval. The species, tissue, clinical status (of CSF donors), synaptic fraction (synapse), protein
identification and number of proteins are shown for each study
Study Species (n) Tissue Clinical status (A)/Fraction analyzed (B–D) Protein identification method
#Proteins
published
(A) Proteomic studies of the CSF
(20) Begcevic Human (6) CSF Non-pathological SCXLC-MS/MS 2615*
(21) Zhang 2015 Human (14) CSF Non-neurological Surgery HPLCLC-MS/MS 2513
(22) Guldbrandsen Human (21) CSF Neurologically healthy RP-AX LC-MS/MS 3081
(23) Holtta Human (3) CSF Neurologically healthy LC-MALDI TOF/TOF 104
(24) Schutzer Human (11) CSF Non-neurologic SCX  LC-MS/MS 2630
(25) Stoop Human (40) CSF Non-neurological Surgery LC-MS & MALDI-FT-ICR-MS 178
(26) Pan 2006 Human (19) CSF Cognitively normal LC-MS/MS 216
(27) Xu Human (22) CSF Cognitively normal SCX  LC-MS/MS 784
(28) Zhang 2005 Human (22) CSF Cognitively normal SCX  LC-MS/MS 312
(29) Wenner Human (10) Postmortem CSF Cognitively normal SCX  LC-MS/MS 249
(B) Proteomic studies of the whole synapse
(30) DiGiorgis Human (3) cortex Synaptosome
(phosphoproteins)
MS/MS 24
(31) Wilhelm Rat (4) cortex &cerebellum Synaptosome iBAQ 1113
(32) Abdul-Husn Mouse (10) hippocampus Presynapse In-gel(26)/In-solution: LC-MS/MS 131
Rat (10) striatum Presynapse In-gel(26)/In-solution: LC-MS/MS 113
(C) Proteomic studies of the active zone/synaptic vesicles (SV)
(33) Weingarten Mouse (12) whole brain Presynaptic active
zone, SV
microOTOF-Q II/MALDI-TOF/TOF 482
(34) Blondeau Rat whole brain SV (Ficoll) In-gel(61): LCMS/MS 209
(35) Boyken Rat whole brain SV (fraction 4–7, 19–21,
vGLUT1/VGAT)
iTRAQ APLC-MS/MS 491
(36) Coughenour Rat forebrain SV (fraction 13–21) In-gel NanosprayMS/MS QTOF 35
(37) Morciano 2005 Rat (3) whole brain SV (fraction 5–11,
28–34/SV2-complex)
In-gel(36) MALDI-TOF 93
(38) Morciano 2009 Rat whole brain SV (fraction 5–11,
28–34/SV2-complex)
In-gel MALDI-TOF-MS/WB 218
(39) Takamori Rat whole brain SV 2D-GE Q-TOF MS 400
(D) Proteomic studies of the post-synaptic density (PSD)/ MASC
(40) Bayés 2011 Human (9) neocortex PSD LC-MS 1451
(41) Fernandez Mouse forebrain PSD (PSD-95complexes) AP  LC-MS/MS LTQ-FT 117
(42) Cheng Rat Forebrain/cerebellum PSD ICAT-LC-MS/MS 238
(44) Li 2004 Rat forebrain PSD 2D-GEMALDI-TOF/TOF 92
(43) Li 2005 Rat forebrain PSD ICAT LC-MS TOF/TOF - ICAT 113
(45) Peng Rat forebrain PSD LC-MS/MS LCQ-DECA XP Ion trap 365
(46) Walikonis Rat forebrain PSD 2D-GE, MALDI-TOF MS 26
(47) Bayés 2012 Mouse (3) cortex PSD LC-MS 1546
(48) Collins 2006 Mouse whole brain PSD SDS-PAGE-LC-MS/MS Q-TOF 617
(49) Trinidad Mouse whole brain PSD SCX Nano-LC-ESI-QTOF MS/MS 242
(50) Bayés 2014 Human neocortex MASC AP-Orbitrap LCMS/MS 289
(48) Collins 2006 Mouse whole brain MASC SDS-PAGE-LC-MS/MS Q-TOF 186
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FIG. 1. Expression of the panel proteins at the human cortical synapse. A, Using AT microscopy, ultrathin tissue slices (70 nm) from human
post-mortem cortical tissue from one brain donor were immunostained for pre- (synaptophysin, red) and post- (PSD95, green) synaptic markers
and the synaptic panel proteins (blue). A representative 3-D reconstruction of a representative synapse is shown for each panel protein. The
segmented immunofluorescence of the 3 proteins in each individual stack (at 70 nm increments) is shown to the right of the reconstruction. Scale
bars representing 1 m are shown at the bottom of each z stack. B, Mean fold-enrichment plotted for each panel protein in homogenate (H),
synaptosome-enriched (S) and PSD-enriched (PSD) fractions taken from post-mortem human cortex (n  6). S/H and PSD/H; intensity in S or PSD
fractions relative to H for the same sample. H/H; intensity in the H fraction for each sample relative to the mean intensity in the H fraction across
all samples. Enrichment of the pre- (synaptophysin) and post (PSD-95) markers are also shown. Degrees of freedom (df), F statistic and p values
for the ANOVA are shown at the top of each plot and Dunnett’s p values are shown for significant pair-wise comparisons (  0.05).
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direct contact. This is consistent with the literature where
Tenascin-R has been reported to reside in extracellular
perineuronal nets that surround the synapse (70).
Specificity of synaptic expression was further evaluated by
quantifying the enrichment of the panel proteins in synapto-
some and PSD fractions extracted from 6 human cortical
tissue samples without pathology (supplemental Table S7).
The 2A isoform of Neurexin-2 could not be analyzed because
of the lack of a commercially-available specific antibody suit-
able for Western blotting. Fig 1B shows that all 9 proteins
tested were enriched in synaptic fractions compared with the
homogenate (p  0.03). Specifically, Calsyntenin-1, Neurexin-
3A, Syntaxin-1B and Vamp-2 were enriched 2.0 to 5.0-fold in
synaptosomes (p  0.02) with Vamp-2 in particular, showing
greater enrichment (5-fold, p  0.0001) than the widely-used
pre-synaptic marker, synaptophysin (3-fold, p  0.0001). Cal-
syntenin-1, GluR2, GluR4, Neuroligin-2, Tenascin-R and
Thy-1 were enriched 1.8 to 5.0-fold in the PSD fraction (p 
0.03). Therefore all 10 proteins are expressed specifically at
the human synapse or in the surrounding area (Tenascin R).
Exploration Phase - Characterizing the CSF Profile of the
Synaptic Panel in AD—Because Tenascin-R, was not directly
expressed at the synapse, this protein was not brought for-
ward for evaluation. Table II provides further information re-
garding the 9 synaptic proteins and their corresponding pep-
tides that were monitored by SRM in the exploratory cohort
comprising 80 CSF samples from controls and all preclinical
and clinical stages of the AD continuum (Table IIIA). Supple-
mental Table S8A lists the transitions included and excluded
from the analysis. Fig 2A shows the relative fold-change in
CSF levels of the 20 individual peptides and summarized
protein levels at each AD stage compared with the cognitively
normal, AD biomarker negative, control group (n  20). sup-
plemental Table S9A shows the raw values. Peptides were not
significantly altered in individuals at preclinical AD stage 1
(n  10) compared with controls, albeit that 17 peptides from
8 proteins were subtly reduced 0.8 to 0.9-fold (p  0.1). At
preclinical AD stage 2 (n  10), no differences were observed
(0.9 to 1.1-fold, p  0.2). In prodromal AD patients (n  20), 19
peptides from 8 proteins were elevated 1.3 to 1.6-fold (p 
0.04, adj.p  0.04). In patients at the dementia stage (n  20),
Calsyntenin-1 (1.2 to 1.3-fold, p  0.02, adj.p  0.1), GluR4
(1.3-fold, p  0.04, adj.p  0.1), Neurexins-2A and 3A and
Thy-1 (1.2 to 1.3-fold, p  0.04, adj.p  0.1) peptides re-
mained elevated. Overall, levels of peptides from the same
protein were highly correlated across all samples (  0.77 to
0.98). Excepting the GluR2 peptide, which showed relatively
elevated levels (p  0.05) at preclinical stage 1, the fold-
changes of all peptides and proteins were comparable to
each other at all disease stages, differing only in significance
level, indicating very little peptide or protein-specific differ-
ences. In fact, the levels of all proteins across all disease
stages were positively correlated (n  80, all 0.37, all p 
7  104), Calsyntenin-1, GluR4, Neurexin-2A, Neurexin-3A,
Neuroligin-2 and Thy-1 in particular (  0.66 to 0.90).
Validation Phase - Validation of the Synaptic CSF Profile in
an Independent AD Cohort—All 20 peptides were brought
forward for validation in an independent clinical cohort com-
prising 60 CSF samples controls and preclinical and clinical
stages of the AD continuum (Table 3B). Supplemental Table
S8B lists the transitions included and excluded from the anal-
ysis. Fig 2B shows the relative fold-change in CSF levels of
the individual peptides and summarized proteins at each AD
stage compared with the cognitively normal, AD biomarker
negative control group (n  18). Supplemental Table S9B
shows the raw values. Like the exploratory cohort, levels of
peptides from the same protein were highly correlated across
all samples (  0.52 to 0.98) and all 20 peptides showed
comparable CSF profiles at all disease stages. All proteins
were positively correlated (n  60, all 0.36 all p  0.005),
GluR4, Neurexin-2A, Neuroligin-2, and Thy-1 in particular ( 
0.61 to 0.80). The greatest fold-change was observed in indi-
viduals at preclinical stage 1 (n  9) in whom Calsyntenin-1,
GluR4, Neurexin-2A, Neurexin-3A, Neuroligin-2, Syntaxin-1,
and Thy-1 peptides were reduced 0.6 to 0.8-fold (p  0.05,
adj.p  0.03 to 0.09). In individuals at preclinical stage 2 (n 
8), Calsyntenin-1 and Vamp-2 peptides were elevated 1.3-fold
(p  0.05, adj.p  0.1). Although all peptides showed positive
fold-changes (1.1 to 1.3-fold) in prodromal AD patients (n 
10), the only peptide to validate the elevated levels observed
in the exploratory analyses was for GluR4, which was ele-
vated 1.3-fold (p  0.04, adj.p  0.5). None of the peptides
were significantly elevated in patients at the dementia stage
(1.0 to 1.2-fold, p  0.09).
Although, all synaptic proteins moderately correlated with
total tau levels, in both cohorts (exploratory; n  80,   0.45
to   0.67, validation; n  60,   0.36 to 0.56), by definition,
total tau levels are unaltered in individuals at preclinical AD
stage 1. Therefore, a reduction of synaptic proteins at preclin-
ical stage 1 would be of increased clinical value because
individuals at this early stage are asymptomatic and have yet
to demonstrate widespread neuronal degeneration. We there-
fore sought to replicate this finding in a larger set of controls
and preclinical AD stage 1 (n  38) from the SPIN cohort.
Supplemental Table S8C lists the transitions included and
excluded from the analysis. Fig 2C shows that compared with
control subjects, Calsyntenin-1, GluR4, Neurexin-2A, Neur-
exin-3A, Syntaxin-1 and Thy-1 were reduced 0.7 to 0.8-fold
(p  0.05). Supplemental Table S9C shows the raw values.
Finally, we performed a cross-cohort meta-analysis by
combining the p values (Fisher’s p value) at each disease
stage for peptides that demonstrated fold-changes in the
same direction across all cohorts. Supplemental Table S9D
shows the raw values. The mean of fold-change for each
peptide at each disease stage is plotted in Fig 2D. In this
meta-analysis, Calsyntenin-1, GluR4, Neurexin-2A, Neurexin-
3A, Syntaxin-1B, and Thy-1 peptides were reduced (0.8-fold,
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Fisher’s p  0.05) in individuals at preclinical AD stage 1,
Calsyntenin-1, GluR2, GluR4, Neurexin-2A, Neurexin-3A,
Neuroligin-2, Thy-1, and Vamp-2 peptides were elevated (1.2
to 1.4-fold, Fisher’s p  0.04) in prodromal AD patients and
Calsyntenin-1, GluR4, Neurexin-2A, and Neurexin-3A were
elevated (1.2 to 1.3-fold, p  0.04) at the dementia stage.
Therefore, these data support a biphasic profile for 5 proteins
(Calsyntenin-1, GluR4, Neurexin-2A, Neurexin-3A, and Thy-1)
whereby compared with controls, CSF peptide levels are re-
duced at the earliest preclinical stage 1 of AD when neurode-
generation has yet to take hold, as indicated by total tau
levels, but elevated at the prodromal AD stage when neuro-
degeneration is widespread.
DISCUSSION
This is the first systematic study of the CSF proteome and
thorough characterization of its synaptic component. Using
this resource, we selected a panel of 10 synaptic proteins for
evaluation as potentially novel biomarkers of synapse degen-
eration in neurological diseases characterized by synaptopa-
thy. We confirmed the specific expression of 9 of the synaptic
proteins at the human cortical neuronal synapse therefore
increasing the probability that their CSF levels are directly
related to synapse integrity. A thorough evaluation of the CSF
profile of the 9 synaptic proteins in three independent clinical
cohorts comprising controls and pre-clinical and clinical
stages of AD revealed a set of six synaptic proteins (Calsyn-
tenin-1, GluR4, Neurexin-2A, Neurexin-3A, Syntaxin-1B and
Thy-1) that were reduced 0.8-fold (p  0.05) at the earliest
preclinical stage of AD (stage 1, cognitively normal with pos-
itive amyloid markers) compared with controls. Five of these
proteins were also elevated in patients at the clinical stages
(cognitive impairment and positive neurodegeneration mark-
ers). We propose that the reduced levels in preclinical stage 1
may reflect reduced synaptic density in these individuals who
already show signs of brain amyloidosis, an effect that is
confounded by widespread neurodegeneration at later dis-
ease stages.
In the discovery stage of this study, a thorough proteomic
screen of 60 CSF samples combined with a literature search
of proteomic studies of the CSF identified 4,315 proteins in
cognitively normal individuals. To put this into context, the
latest release of the Human Protein Atlas (v17) comprises
RNA expression for 10,226 unique genes that were positively
detected in the brain (cortex, cerebellum or hippocampus), of
which we report that 26% are detectable in the CSF. Accord-
ing to the Human Protein Atlas data, we estimate that 79% of
the brain-expressed proteins detected in the CSF are known
to be expressed in the cortex, 65% in the hippocampus and
67% in the cerebellum.
FIG. 2. Synaptic panel peptide levels in the CSF across the AD continuum. The log2 fold-change (	 standard error; S.E.) in CSF levels
of the synaptic panel peptides and summarized protein levels are plotted for each preclinical and clinical AD stage versus cognitively normal
controls for (A) the exploratory cohort (Controls n  20, Stage1 n  10, Stage2 n  10, Prodromal n  20, AD dementia n  20), (B) validation
cohort-1 (Controls n  18, Stage1 n  9, Stage2 n  8, Prodromal n  10, AD dementia n  15), (C) validation cohort-2 (Controls n  20,
Stage1 n  18) and (D) the combined mean log2 fold-change across the 3 cohorts. For ease of interpretation, the natural values are labeled
on the y axis on a log2 scale. The linestyle of the error bars were determined by p value cut-offs for pair-wise group comparisons using a mixed
effect linear regression model (see legend). Stage1; preclinical AD stage 1, Stage2; preclinical stage 2,Prodromal; prodromal AD, Dementia; AD
dementia.
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We then searched the literature and public databases for
proteins that are both physically and functionally related to the
synapse, thereby prioritizing well-characterized synaptic pro-
teins. The 537 proteins retrieved represent 4% of those with
positive RNA brain expression data included in the Human
Protein Atlas database, suggesting that this is a relatively
stringent classification. Regional expression data from the
Human Protein Atlas provide evidence for 95% of these syn-
aptic transcripts in the cerebral cortex, 75% in the hippocam-
pus and 87% in the cerebellum. We conclude that most of the
proteins we have classified as synaptic are expressed across
multiple brain regions. This lack of regional specificity offers
the possibility that these proteins could be informative across
the range of neurological and psychiatric diseases, which
demonstrate distinct regional susceptibility. Notably, our CSF
database included 47% of these synaptic proteins. When
compared with the 26% yield of brain-expressed proteins in
CSF, we conclude that the coverage of synaptic proteins in
our CSF database was relatively high.
In the verification stage, we employed AT microscopy, a
technique especially suited to study single synapses (17, 18)
to verify the synaptic expression of a set of proteins detect-
able in the CSF by SRM and with a known synaptic function
at the human cortical synapse. With improved antibody pen-
etration compared with other super resolution techniques and
improved resolution compared with traditional confocal mi-
croscopy, we report with high confidence that our panel of 9
proteins are expressed directly at or surrounding human cor-
tical neuronal synapses. The synaptic panel includes proteins
with a range of synaptic functions, including but not limited to,
spine assembly and maturation, synaptic transmission and
plasticity, synaptogenesis and synaptic vesicle exocytosis.
No clear difference in CSF profile could be attributed to any
function. The protein expression of 7 of these proteins has
been assessed by the Human Protein Atlas, all of which were
detected in the cortical neuropil. Calsyntenin-1 and Neuroli-
gin-2 were the only proteins detected, at low levels, in glial
cells. Consistent with the extracellular expression in perineu-
ronal nets, Tenascin-R was detected in the neuropil but not in
neurons or glia, further supporting its exclusion from the re-
mainder of the study. In AD, reduced brain expression at the
transcriptomic or proteomic level has been reported for
GluR2, GluR4, Neurexin-2A, Syntaxin-1B, Tenascin-R, Thy-1,
and VAMP-2, whereas increased expression has been re-
ported for Neuroligin-2 (71–74). Pertinently, there is evidence
in the literature that some of the panel proteins may be in-
volved in mechanisms directly related to AD pathogenesis.
For example, GluR2, (75) GluR4 (76), and Neurexin-2A (77)
have been postulated as direct targets of A oligomers. Ad-
ditionally, there is evidence that Calsyntenin-1 (78, 79) and
Vamp-2 (80) play a role in A production, trafficking or secre-
tion and a role for the Neurexin-Neuroligin complex in regu-
lating A metabolism and function has also been postulated
(81). The potential involvement of these proteins in AD patho-
genesis makes these proteins particularly attractive candidate
biomarkers for AD. This does not exclude their potential as
biomarkers of synapse loss in other neurological diseases.
Defective GluR2 RNA editing may be relevant to amyotrophic
lateral sclerosis (82), whereas variations in genes encoding
Neuroligin-2, Neurexin-3 and Syntaxin-1B have been impli-
cated in schizophrenia (83), autism spectrum disorder (84)
and epilepsy (85), respectively.
In the exploration and validation stages of this study, we
quantified the 9 synapse-verified proteins in three independ-
ent clinical cohorts of CSF samples from cognitively normal
controls and individuals from the AD continuum. As has been
reported for other synaptic proteins, such as neurogranin (86),
synaptotagmin-1 (10) and SNAP-25 (9), we observed an in-
crease in CSF levels of 8 of the panel proteins in prodromal
AD patients compared with controls. The moderate correla-
tion of the synaptic panel proteins with a marker of tau-
mediated neurodegeneration suggests that synapse and neu-
ronal loss are interrelated in AD and that the panel proteins
partially reflect both processes. GluR2, Neurexin-2A, Neuroli-
gin-2, Syntaxin-1B, and Vamp-2 showed a weaker correlation
with CSF total tau than that reported for neurogranin, synap-
totagmin and SNAP-25. It remains to be determined whether
the greater independence of these proteins from CSF tau
levels compared with other synaptic proteins provides addi-
tional clinical value when used as biomarkers. We also report
that 12 peptides from Calsyntenin-1, GluR4, Neurexin-2A,
Neurexin-3A, and Thy-1 were reduced at preclinical AD stage
1. Our data support that reduced levels of synaptic proteins in
the CSF reflect a reduced synaptic density in these individu-
als, which is only apparent when not being masked by wide-
spread neurodegeneration. These proteins could be valuable
markers for monitoring disease progression in at-risk individ-
uals before the appearance of cognitive symptoms.
In conclusion, we have identified and provided clinical val-
idation for a set of synaptic proteins (Calsyntenin-1, GluR4,
Neurexin-2A, Neurexin-3A, Syntaxin-1B, and Thy-1) that can
be detected in CSF by targeted liquid chromatography mass
spectrometry without depletion, immunoprecipitation or frac-
tionation of the sample that could provide added value in the
clinical setting to assess disease progression in individuals
at-risk for AD and AD patients and could improve enrichment
and monitoring of drug efficacy in pharmaceutical drug trials.
To our knowledge, this is the first study to demonstrate a
non-linear profile of a subset of synaptic proteins in AD with
changes observed at the earliest preclinical AD stage before
neurodegeneration is widespread. This study serves as a
basis for future research on the dynamics of synaptic proteins
in the CSF. Because the cross-sectional design of the current
study does not allow assessment of the prognostic capacity
of the synaptic panel proteins, future longitudinal studies in
large cohorts are necessary to further explore the potential of
the synaptic panel proteins as prognostic biomarkers that
precede markers of neurodegeneration. The potential of the
Synaptic Panel Alzheimer’s Disease CSF
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proteins described herein to be useful prognostic biomarkers
across a range of neurological and psychiatric disease opens
many avenues for further investigation.
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the television channel, TV3 (201426 10). OB is supported by the
Miguel Servet program (CP13/00091) from the ISCIII and FEDER. AB
is supported by the Ministerio de Economia y Competitividad, Gobi-
erno de España and FEDER (BFU2012-34398 and BFU2015-69717-
P), by the Career Integration Grant from the European Union (ref.
304111, Marie Curie Actions), by the Ramón y Cajal Fellowship (ref.
RYC-2011-08391) from the Ministerio de Economia y Competitividad,
Gobierno de España and by the CERCA Programme from the Gen-
eralitat de Catalunya. RN-L is supported by the research grant from
the Generalitat de Catalunya (PERIS SLT/2381/2016/00099). The pro-
teomics analyses were performed in the CRG/UPF Proteomics Unit
which is part of the Proteored, PRB3 and is supported by grant
PT17/0019, of the PE IDi 2013–2016, funded by ISCIII and ERDF.
□S This article contains supplemental material.
The authors declare that the Biomedical Research Institute Sant
Pau (IIB Sant Pau) has filed a patent application (pending) to the
European Patent Office (EP18382175.0) to protect the intellectual
property included in this manuscript. O Belbin, A Lleó, Á Bayés, J
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